SEATTLE, Wash. and VANCOUVER, British Columbia, February 24, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT Annual Meeting being held virtually. An overview of the data can be also accessed by visiting https://ir.achievelifesciences.com/srnt2021.
- “A Survey in the United States of Attitudes to Nicotine Cessation in Smokers: Smokers’ Satisfaction with Available Treatments” (PH-293): Results from a recent survey of 1,122 current and former smokers indicated the overall satisfaction and perceived efficacy of available cessation treatments was low. A majority of smokers who use prescription medications to quit smoking do not complete the 3-month course of therapy and concerns about side effects are reported as the key reason for non-compliance, or refusal to initiate treatment with Chantix® (varenicline) or bupropion.
- “A Survey in the United States of Attitudes to Nicotine Cessation in Vapers: Reasons for Choosing to Vape” (PH-294) Survey results from 508 users of nicotine vape products showed that the primary reason to initiate e-cigarettes/vaping was to quit combustible cigarettes. While proven successful in the cohort of subjects who only utilize vape, dual users, those who vape but also continue to smoke, reported 2-times heavier nicotine use than their counterparts. These data suggest that dual users become more heavily addicted to nicotine due to vaping.
- “A Survey in the United States of Attitudes to Nicotine Cessation in Vapers: Their Plans to Quit Vaping” (PH-295) Data from 508 users of nicotine vape products indicated that 73% of e-cigarette/vape users intend to quit vaping in the next 3-12 months. Of those who intend to do so in the next 3 months, more than half reported they would be “very/extremely likely to try a new prescription product” to help them quit.
“This real-world evidence supports the critical need for a new therapeutic option for smokers and e-cigarette users who are unable to tolerate, or refuse to take, currently available treatments due to side effects or negative product perceptions,” commented John Bencich, CEO of Achieve. “We know that more than 75% of Chantix users are not completing the 3-month treatment, and we believe the tolerability profile of cytisinicline, as shown in trials to date, may help smokers remain on treatment and lead to better outcomes for those battling nicotine addiction.”
Achieve is currently enrolling smokers in the 750-subject, Phase 3, ORCA-2 study of cytisinicline at 15 sites the U.S. For more information on cytisinicline and the ORCA-2 study, visit www.achievelifesciences.com or www.orca-2.com.
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a milli